Paul Peter Tak is CEO at Candel Therapeutics, Inc. (CADL). They have made 7 open-market trades across 1 company since 2021, most recently 2026-09-11.
CIK 0001873905
2 open-market purchases totalling $230K since 2021, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CADL | 113,321 | $927K |
Shares reported on the most recent Form 4, priced at the 2026-09-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CADL | SELL · 10b5-1 | 2026-09-10 | 2026-09-11 | $11.28 | $3.2M | +6.0% | -8.0% | — |
| CADL | SELL · 10b5-1 | 2025-03-18 | 2025-03-20 | $8.77 | $456K | -33.3% | -46.0% | -41.1% |
| CADL | SELL | 2025-01-15 | 2025-01-17 | $7.23 | $314K | +2.1% | +39.6% | -33.0% |
| CADL | SELL | 2025-01-08 | 2025-01-10 | $8.22 | $348K | -13.1% | +6.8% | -41.3% |
| CADL | SELL | 2024-11-29 | 2024-12-03 | $4.56 | $445K | +45.2% | +93.3% | +70.1% |
| CADL | SELL | 2024-07-17 | 2024-07-19 | $6.47 | $292K | -1.3% | -12.6% | -2.3% |
| CADL | SELL | 2024-07-11 | 2024-07-15 | $5.97 | $242K | -1.5% | -20.4% | -9.2% |
| CADL | BUY | 2022-12-08 | 2022-12-12 | $1.88 | $30K | -34.7% | -27.5% | -40.8% |
| CADL | BUY | 2021-07-29 | 2021-08-02 | $8.00 | $200K | +4.6% | +0.9% | +48.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.